ClinicalTrials.gg
TerminatedNCT05268289Updated Nov 12, 2026

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

A Phase 2 interventional study of Iptacopan (part 1) and Iptacopan (part 2) in Lupus Nephritis, sponsored by Novartis Pharmaceuticals. Terminated at 38 sites in 16 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The decision to conclude the study after Part 1 LPLV is based on strategic considerations by the Sponsor.
Updated Nov 12, 2026Now TerminatedNo longer in 4 countries+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Lupus Nephritis by Novartis — 1 open to participants now, 3 under way, 2 of them phase 3. Lupus Nephritis · Novartis.

Started
2022
with 2 others
Phase 2
4 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Lupus Nephritis by Novartis, this one is one of 3 that started in 2022, is one of 4 in phase 2, and was the 7th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

1 of the 10 studies in Lupus Nephritis by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lupus Nephritis by Novartis, or all of them as a file.
02

Study summary

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Read the detailed description

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

03

Conditions studied

  • Lupus Nephritis

Keywords

  • LNP023
  • Iptacopan
  • Lupus Nephritis
  • proteinuria
  • Urine Protein-to-Creatinine Ratio
  • complete renal response
  • estimated glomerular filtration rate
  • renal flares
  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active -proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.

Documentation of active renal disease at the time of screening necessitating the commencement of therapy with in combination with MMF/MPS.

≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless , ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.

First presentation or flare of lupus nephritis.

Exclusion criteria

Exclusion Criteria:

Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.

Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in within 3 months prior to screening.

Renal presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to therapy.

Participants being treated with systemic (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.

Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Active comparator
    Iptacopan + standard of care (part 1)

    Iptacopan + standard of care

    Drug: Iptacopan (part 1)

  • Placebo comparator
    Placebo matching iptacopan + standard of care (part 1)

    Placebo matching iptacopan standard of care

    Drug: Placebo + standard of care

  • Active comparator
    Iptacopan + standard of care (part 2)

    Iptacopan + standard of care

    Drug: Iptacopan (part 2)

  • Active comparator
    Iptacopan + placebo (part 2)

    Iptacopan + placebo standard of care

    Drug: Iptacopan + placebo

  • Active comparator
    Placebo matching iptacopan + standard of care (part 2)

    Placebo matching iptacopan + standard of care

    Drug: Placebo + standard of care

Interventions

  • DrugIptacopanStudies of IptacopanIptacopan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Taken for 52 Weeks

    Also known as: LNP023

  • DrugIptacopanStudies of IptacopanIptacopan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Taken for 52 Weeks

    Also known as: LNP023

  • DrugPlacebo + standard of care

    Taken for 52 Weeks

  • DrugIptacopan + placebo

    Taken for 52 Weeks

    Also known as: LNP023 and placebo

06

What researchers measure

Primary outcomes

  1. Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares

    Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g.

    Time frame: Baseline and week 24

Secondary outcomes

  1. Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares

    Proportion of patients achieving complete renal response or partial renal response

    Time frame: Baseline, week 24, week 52

  2. Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24

    Frequency of renal flares between weeks 24 and 52

    Time frame: Baseline, week 24 week 52

  3. Log-transformed ratio to baseline of 24h UPCR at week 24

    Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit)

    Time frame: Baseline week 24

  4. Change from baseline FACIT-Fatigue Score

    Measure fatigue in patients

    Time frame: Weeks 24 and 52

  5. Change from baseline in SLEDAI-2K score at weeks 24 and 52

    Measure disease activity in SLE

    Time frame: Weeks 24 and 52

  6. Change from baseline in BILAG-2004 score at weeks 24 and 52

    Measure disease activity

    Time frame: Weeks 24 and 52

  7. Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples

    Measurement of time to complete renal response based on urine samples

    Time frame: Week 24 and Week 52

07

Study locations

38 sites
  • Loma Linda University
    San Bernardino, California 92408, United States
  • Nep Assoc of Northern Illinois
    Hinsdale, Illinois 60521, United States
  • Novartis Investigative Site
    Santa Fe, S3000EPV, Argentina
  • Novartis Investigative Site
    Salvador, Estado de Bahia 40150-150, Brazil
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 04038-002, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 05403-000, Brazil
  • Novartis Investigative Site
    Salvador, 40323-010, Brazil
  • Novartis Investigative Site
    Nanning, Guangxi 530022, China
  • Novartis Investigative Site
    Yinchuan, Ningxia 750004, China
  • Novartis Investigative Site
    Shenzhen, 518036, China
  • Novartis Investigative Site
    Barranquilla, Atlántico 080020, Colombia
  • Novartis Investigative Site
    Bogota, Cundinamarca 111411, Colombia
  • Novartis Investigative Site
    Bucaramanga, Santander Department 680003, Colombia
  • Novartis Investigative Site
    Montería, 230004, Colombia
  • Novartis Investigative Site
    Marseille, 13005, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Braunschweig, Lower Saxony 38126, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Hong Kong, Hong Kong 999077, Hong Kong
  • Novartis Investigative Site
    Kozhikode, Kerala 673008, India
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110029, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500082, India
  • Novartis Investigative Site
    Kuantan, Pahang 25100, Malaysia
  • Novartis Investigative Site
    Taiping, Perak 34000, Malaysia
  • Novartis Investigative Site
    Selangor Darul Ehsan, 68100, Malaysia
  • Novartis Investigative Site
    Tampico, Tamaulipas 89440, Mexico
  • Novartis Investigative Site
    Mérida, Yucatán 97070, Mexico
  • Novartis Investigative Site
    Aguascalientes, 20230, Mexico
  • Novartis Investigative Site
    Veracruz, 91900, Mexico
  • Novartis Investigative Site
    Makati City, National Capital Region 1218, Philippines
  • Novartis Investigative Site
    Quezon, 1102, Philippines
  • Novartis Investigative Site
    Coimbra, 3004-561, Portugal
  • Novartis Investigative Site
    Singapore, Singapore 308433, Singapore
  • Novartis Investigative Site
    Kayseri, Melikgazi 38039, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Yenimahalle 06500, Turkey (Türkiye)
  • Novartis Investigative Site
    Mersin, Yenisehir 33110, Turkey (Türkiye)
  • Novartis Investigative Site
    Cambridge, CB2 0QQ, United Kingdom
08

References and documents

Publications

  • Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230. PubMed 37528520 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2022 to primary completion in Mar 2026, 43 months.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2028 → Oct 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2022
First posted
Mar 7, 2022
StartActual
Aug 10, 2022
Primary completionActual
Mar 19, 2026
CompletionActual
Oct 1, 2026was Sep 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The decision to conclude the study after Part 1 LPLV is based on strategic considerations by the Sponsor.
changed Oct 15, 2026
Sites
1 site added, 66 sites removed; no longer in Israel, Hungary, Puerto Rico and Spain. 6 sites changed recruiting status (3 now withdrawn, 2 now completed, …)
Show 6 sites
  • Loma Linda University · San Bernardino, United StatesActive, not recruiting→Completed
  • Mayo Clinic Jacksonville · Jacksonville, United StatesRecruiting→Withdrawn
  • University of Nebraska Medical Center · Omaha, United StatesActive, not recruiting→Withdrawn
  • Virginia Commonwealth University · Richmond, United StatesRecruiting→Withdrawn
  • Novartis Investigative Site · Bucaramanga, ColombiaActive, not recruiting→Completed
  • Novartis Investigative Site · Debrecen, HungaryRecruiting→Active, not recruiting
Show site
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Show 66 removed
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
  • AKDHC Medical Research ServicesLLC · Phoenix, United States
  • Kaiser Permanente Fontana · Fontana, United States
  • Univ Calif Irvine · Irvine, United States
  • Mayo Clinic Jacksonville · Jacksonville, United States
  • Florida Kidney Physicians · Riverview, United States
  • Brigham and Womens Hosp Harvard Med School · Boston, United States
  • Mayo Clinic Rochester · Rochester, United States
  • University of Nebraska Medical Center · Omaha, United States
  • Allegheny Health Network · Pittsburgh, United States
  • Virginia Commonwealth University · Richmond, United States
  • Novartis Investigative Site · Rosario, Argentina
  • Novartis Investigative Site · San Luis, Argentina
  • Novartis Investigative Site · Paris, France
  • Novartis Investigative Site · Strasbourg, France
  • Novartis Investigative Site · Munich, Germany
  • Novartis Investigative Site · Ludwigshafen, Germany
  • Novartis Investigative Site · Frankfurt am Main, Germany
  • Novartis Investigative Site · Berlin, Germany
  • Novartis Investigative Site · Ahmedabad, India
  • Novartis Investigative Site · Vellore, India
  • Novartis Investigative Site · Puducherry, India
  • Novartis Investigative Site · Ashkelon, Israel
  • Novartis Investigative Site · Jerusalem, Israel
  • Novartis Investigative Site · Ramat Gan, Israel
  • Novartis Investigative Site · Iloilo City, Philippines
  • Novartis Investigative Site · Porto, Portugal
  • Novartis Investigative Site · Port de Sagunt, Spain
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
  • Novartis Investigative Site · Leicester, United Kingdom
  • …and 36 more on the registry record
across 3 updates, Oct 1, 2026 – Nov 12, 2026
Study completion
Sep 28, 2028→Oct 1, 2026 (actual)
Oct 15, 2026
Enrollment
240 (estimated)→81 (actual)
Oct 15, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Mayo Clinic Jacksonville · Jacksonville, United StatesContact removed W•••@mayo.edu · •••7648Contact removed (no phone or email listed)
  • Ochsner Health System · New Orleans, United StatesContact g•••@ochsner.org · •••3930→r•••@ochsner.org · •••3930
  • Virginia Commonwealth University · Richmond, United StatesContact removed K•••@vcuhealth.org · •••0180Contact removed (no phone or email listed)
Oct 1, 2026
Show all 3 updates
  1. Nov 12, 2026
    36 sites removed; no longer in Hungary, Puerto Rico and Spain
    Show 36 removed
    • Ronald Reagan UCLA Medical Center · Los Angeles, United States
    • Olive View UCLA Medical Center · Sylmar, United States
    • University of Colorado Denver · Aurora, United States
    • Royal Research Corp · Hollywood, United States
    • Nephrology Associates Of Central FL · Orlando, United States
    • Florida Kidney Physicians · Riverview, United States
    • Wichita Community Clcl Onco Program · Wichita, United States
    • Ochsner Health System · New Orleans, United States
    • Johns Hopkins Hospital · Baltimore, United States
    • Stony Brook Internists PC · East Setauket, United States
    • Cleveland Clinic Foundation · Cleveland, United States
    • Temple University · Philadelphia, United States
    • Dallas Nephrology Associates · Dallas, United States
    • Prolato Clinical Research Center · Houston, United States
    • Novartis Investigative Site · Juiz de Fora, Brazil
    • Novartis Investigative Site · Barretos, Brazil
    • Novartis Investigative Site · São Paulo, Brazil
    • Novartis Investigative Site · Wuhan, China
    • Novartis Investigative Site · Shenyang, China
    • Novartis Investigative Site · Beijing, China
    • Novartis Investigative Site · Cologne, Germany
    • Novartis Investigative Site · Debrecen, Hungary
    • Novartis Investigative Site · Budapest, Hungary
    • Novartis Investigative Site · Szeged, Hungary
    • Novartis Investigative Site · Lucknow, India
    • Novartis Investigative Site · Carnaxide, Portugal
    • Novartis Investigative Site · Lisbon, Portugal
    • Novartis Investigative Site · Vila Nova de Gaia, Portugal
    • FDI Clinical Research · San Juan, Puerto Rico
    • Novartis Investigative Site · Barcelona, Spain
    • …and 6 more on the registry record
    + 1 other change: verification date
  2. Oct 15, 2026
    Recruiting→Terminated
    Why stopped The decision to conclude the study after Part 1 LPLV is based on strategic considerations by the Sponsor.
    29 sites removed; no longer in Israel
    Show 29 removed
    • AKDHC Medical Research ServicesLLC · Phoenix, United States
    • Kaiser Permanente Fontana · Fontana, United States
    • Univ Calif Irvine · Irvine, United States
    • Mayo Clinic Jacksonville · Jacksonville, United States
    • Florida Kidney Physicians · Riverview, United States
    • Brigham and Womens Hosp Harvard Med School · Boston, United States
    • Mayo Clinic Rochester · Rochester, United States
    • University of Nebraska Medical Center · Omaha, United States
    • Allegheny Health Network · Pittsburgh, United States
    • Virginia Commonwealth University · Richmond, United States
    • Novartis Investigative Site · Rosario, Argentina
    • Novartis Investigative Site · San Luis, Argentina
    • Novartis Investigative Site · Paris, France
    • Novartis Investigative Site · Strasbourg, France
    • Novartis Investigative Site · Munich, Germany
    • Novartis Investigative Site · Ludwigshafen, Germany
    • Novartis Investigative Site · Frankfurt am Main, Germany
    • Novartis Investigative Site · Berlin, Germany
    • Novartis Investigative Site · Ahmedabad, India
    • Novartis Investigative Site · Vellore, India
    • Novartis Investigative Site · Puducherry, India
    • Novartis Investigative Site · Ashkelon, Israel
    • Novartis Investigative Site · Jerusalem, Israel
    • Novartis Investigative Site · Ramat Gan, Israel
    • Novartis Investigative Site · Iloilo City, Philippines
    • Novartis Investigative Site · Porto, Portugal
    • Novartis Investigative Site · Port de Sagunt, Spain
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    • Novartis Investigative Site · Leicester, United Kingdom
    Study completion Sep 28, 2028→Oct 1, 2026 (now actual)
    Enrollment 240 (estimated)→81 (actual)
    + 2 other changes: verification date and contact details
  3. Oct 1, 2026
    1 site added, 1 site removed. 6 sites changed recruiting status (3 now withdrawn, 2 now completed, …)
    Show 6 sites
    • Loma Linda University · San Bernardino, United StatesActive, not recruiting→Completed
    • Mayo Clinic Jacksonville · Jacksonville, United StatesRecruiting→Withdrawn
    • University of Nebraska Medical Center · Omaha, United StatesActive, not recruiting→Withdrawn
    • Virginia Commonwealth University · Richmond, United StatesRecruiting→Withdrawn
    • Novartis Investigative Site · Bucaramanga, ColombiaActive, not recruiting→Completed
    • Novartis Investigative Site · Debrecen, HungaryRecruiting→Active, not recruiting
    Show site
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Show 1 removed
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Mayo Clinic Jacksonville · Jacksonville, United StatesContact removed W•••@mayo.edu · •••7648Contact removed (no phone or email listed)
    • Ochsner Health System · New Orleans, United StatesContact g•••@ochsner.org · •••3930→r•••@ochsner.org · •••3930
    • Virginia Commonwealth University · Richmond, United StatesContact removed K•••@vcuhealth.org · •••0180Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05268289
Responsible party
Sponsor
First posted
Mar 7, 2022
Start date
Aug 10, 2022
Primary completion
Mar 19, 2026
Completion
Oct 1, 2026
Last update
Nov 12, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion